How have RHHVF shares performed in 2024?

Roche's stock was trading at $285.00 at the beginning of the year. Since then, RHHVF shares have decreased by 15.8% and is now trading at $240.06. View the best growth stocks for 2024 here .

Are investors shorting Roche?

Roche saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 1,895,900 shares, an increase of 22.7% from the February 29th total of 1,544,800 shares. Based on an average daily volume of 3,900 shares, the short-interest ratio is presently 486.1 days. View Roche's Short Interest .

Is Roche a good dividend stock?

Roche (OTCMKTS:RHHVF) pays an annual dividend of $7.80 per share and currently has a dividend yield of 3.21%. The dividend payout ratio is 72.16%. This payout ratio is at a healthy, sustainable level, below 75%.

How do I buy shares of Roche?

Shares of RHHVF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:RHHVF

Roche (RHHVF) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Free RHHVF Stock Alerts

$240.06

-2.56 (-1.06%)

(As of 04/18/2024 ET)

Compare

Today's Range: $236.98
▼
$243.80
50-Day Range: $240.06
▼
$279.39
52-Week Range: $237.81
▼
$323.78

Volume: 1,675 shs
Average Volume: 9,687 shs
Market Capitalization: N/A

P/E Ratio: 22.21
Dividend Yield: 3.25%
Price Target: N/A

Stock Analysis Chart Headlines Short Interest

Get Roche alerts:

Roche MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Bearish
Dividend Strength: Weak
Based on Four Factors
Sustainability: N/A
News Sentiment: -0.27
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.08 out of 5 stars

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Roche.

0.0

Short Interest

Percentage of Shares Shorted
Short Interest Ratio / Days to Cover
Roche has a short interest ratio ("days to cover") of 435.4, which indicates bearish sentiment.
Change versus previous month
Short interest in Roche has recently increased by 12.54%, indicating that investor sentiment is decreasing significantly.

1.7

Dividend Strength

Dividend Yield
Roche pays a meaningful dividend of 3.21%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Roche does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Roche is 72.16%. This payout ratio is at a healthy, sustainable level, below 75%.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for RHHVF.

1.5

News and Social Media Coverage

News Sentiment
Roche has a news sentiment score of -0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Roche this week, compared to 1 article on an average week.
MarketBeat Follows
1 people have added Roche to their MarketBeat watchlist in the last 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Roche insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 29.01% of the stock of Roche is held by institutions.

1.3

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Roche is 22.21, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 147.65.
Price to Earnings Ratio vs. Sector
The P/E ratio of Roche is 22.21, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 270.43.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Roche Stock (OTCMKTS:RHHVF)

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.

RHHVF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

RHHVF Stock News Headlines

April 17, 2024 | seekingalpha.com

Tempest Therapeutics: Multiple 2024 Catalysts Make This A Must Watch

April 13, 2024 | morningstar.com

Roche Holding AG RHHVF

April 19, 2024 | American Alternative (Ad)

Your Money is Not Safe

Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…

April 12, 2024 | markets.businessinsider.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Bristol-Myers Squibb (BMY) and Roche Holding AG (OtherRHHVF)

March 31, 2024 | seekingalpha.com

Outlook Therapeutics: De-Risked Regulatory Tracks Are Lining Up For Possible ONS-5010 Approval

March 20, 2024 | markets.businessinsider.com

Lonza To Acquire U.S. Biologics Site From Roche For $1.2 Bln

March 17, 2024 | seekingalpha.com

Poseida: April 2024 Data Could Shed Light On Differentiated CAR-T Advancement

March 11, 2024 | seekingalpha.com

International Wide-Moat Stocks On Sale - The March 2024 Heat Map

April 19, 2024 | American Alternative (Ad)

Your Money is Not Safe

February 26, 2024 | markets.businessinsider.com

Roche Holding AG (RHHVF) Gets a Hold from Jefferies

February 18, 2024 | finance.yahoo.com

FDA approves Xolair as first and only medicine for children and adults with one or more food allergies

February 11, 2024 | seekingalpha.com

Roche: The Recent Sell-Off Created A 30% Upside Potential

February 2, 2024 | reuters.com

Roche Holding AG

February 2, 2024 | markets.businessinsider.com

Barclays Keeps Their Hold Rating on Roche Holding AG (RHHVF)

February 1, 2024 | msn.com

Roche Holding Non-GAAP EPS of CHF 18.57, revenue of CHF 58.72B; initiates FY24 outlook

January 30, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF), Privia Health Group (PRVA) and Natera (NTRA)

January 30, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF), Privia Health Group (PRVA) and Natera (NTRA)

January 15, 2024 | markets.businessinsider.com

Analysts Conflicted on These Healthcare Names: Lantheus (LNTH) and Roche Holding AG (OtherRHHVF)

January 15, 2024 | markets.businessinsider.com

Analysts Conflicted on These Healthcare Names: Lantheus (LNTH) and Roche Holding AG (OtherRHHVF)

January 10, 2024 | markets.businessinsider.com

Analysts Are Neutral on Top Healthcare Stocks: Revance Therapeutics (RVNC), Roche Holding AG (RHHVF)

January 10, 2024 | markets.businessinsider.com

Analysts Are Neutral on Top Healthcare Stocks: Revance Therapeutics (RVNC), Roche Holding AG (RHHVF)

January 5, 2024 | uk.investing.com

Roche Holding AG Participation (RHHVF)

January 5, 2024 | uk.investing.com

Roche Holding AG Participation (RHHVF)

December 11, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: CVS Health (CVS), Vor Biopharma (VOR) and Roche Holding AG (OtherRHHVF)

December 11, 2023 | msn.com

Why Is Cancer Focused Poseida Therapeutics Stock Trading Higher Today?

December 11, 2023 | finance.yahoo.com

New data for Roche’s Columvi and Lunsumio presented at ASH 2023 support continued benefit for people with lymphoma

December 10, 2023 | finance.yahoo.com

New Data for Genentech’s Columvi and Lunsumio Presented at ASH 2023 Support Continued Benefit for People With Lymphoma

See More Headlines

Receive RHHVF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Roche and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Drug Manufacturers - General
Sub-Industry: N/A
Current Symbol: OTCMKTS:RHHVF
CUSIP: N/A
CIK: N/A
Web: www.roche.com
Phone: (161) 688-1111
Fax: N/A
Employees: 103,605
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: 22.21
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Dr. Severin Schwan Ph.D. (Age 57)
Executive Chairman
Comp: $8.23M
Dr. Thomas Schinecker (Age 49)
Chief Executive Officer
Comp: $4.24M
Dr. Alan Hippe (Age 57)
Chief Financial & Information Officer
Comp: $4.5M
Dr. Bruno Eschli
Head of Investor Relations
Ms. Claudia Bockstiegel (Age 60)
General Counsel
Ms. Pascale Schmidt (Age 51)
Chief Compliance Officer
Ms. Barbara Schadler (Age 62)
Head of Group Communications
Ms. Cristina A. Wilbur (Age 57)
Chief People Officer
Comp: $3.2M
Dr. Nicolas Dunant
Head of Group Media Relations
Mr. Boris L. Zaitra (Age 52)
Head of Group Business Development and M&A

Key Competitors

View All Competitors

RHHVF Stock Analysis - Frequently Asked Questions

How have RHHVF shares performed in 2024?: Roche's stock was trading at $285.00 at the beginning of the year. Since then, RHHVF shares have decreased by 15.8% and is now trading at $240.06.
View the best growth stocks for 2024 here.
Are investors shorting Roche?: Roche saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 1,895,900 shares, an increase of 22.7% from the February 29th total of 1,544,800 shares. Based on an average daily volume of 3,900 shares, the short-interest ratio is presently 486.1 days.
View Roche's Short Interest.
Is Roche a good dividend stock?: Roche (OTCMKTS:RHHVF) pays an annual dividend of $7.80 per share and currently has a dividend yield of 3.21%. The dividend payout ratio is 72.16%. This payout ratio is at a healthy, sustainable level, below 75%.
How do I buy shares of Roche?: Shares of RHHVF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:RHHVF) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial